Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
James Januzzi, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Alexander J. Blood, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Om P. Ganda, MD
Antoni Bayés-Genís, MD, PhD
Patrick Rossignol, MD, PhD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.